Novo Nordisk Investor Presentation - First Nine Months of 2016
Investor presentation
First nine months of 2016
Slide 89
Haemophilia is a rare disease with severe unmet medical
needs
Number of people with haemophilia A and B
and haemophilia with inhibitors
Low diagnosis and treatment rates
within haemophilia
Average percentage of people
with haemophilia
Number of
people (000)
500
Haemophilia A
Haemophilia B
400
App. 350,000 patients
App. 70,000 patients
300
45%
Inhibitor
segment app.
3,500-4,000
patients
200
100
15%
6%
3%
0
People with
haemophilia
Diagnosed
Treated
Prophylactic Pristine joints
Note: The inhibitor segment represents people with haemophilia and high titre inhibitors to their normal
replacement treatment
Source: Estimates based on prevalence data in literature (Stonebraker JS et al. Haemophilia. 2010; 16:
20-32), World Federation of Haemophilia - Annual Global Survey 2012, UDC database in the US
changing
diabetes®
Source: World Federation of Haemophilia - Annual Global Survey 2012
novo nordiskView entire presentation